Trans-pulmonary Biomarkers in Pulmonary Hypertension

Running, not enrolling

Conditions studied: Pulmonary Hypertension

In brief

The investigators are testing whether the addition of Pulmonary Hypertension-related biomarkers, measured across the pulmonary circulation, to the standard hemodynamic evaluation for Pulmonary Hypertension will lead to more informed choices of Pulmonary Hypertension therapy and improved patient outcomes.

Key facts

Study ID

NCT01961232

Run by

Vanderbilt University

People needed

100

Starts

2013-08-01

Expected to finish

2027-06-01

Last updated by the study team

2026-03-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years old
• Undergoing RHC for PH evaluation

You may not qualify if…

• Anemia defined as Hgb < 10 g/dL and HCT < 30
• Pregnancy at the time of RHC (as assessed by urine or serum pregnancy test on the day of the procedure)
• Left ventricular ejection fraction ≤ 40%
• Atrial fibrillation at the time of RHC (as defined by telemetry monitoring or EKG on the day of the procedure)
• IPF, CTEPH, COPD/OSA as the dominant etiology of PH
• Patient is currently taking PH medication or long-acting nitrates at the time of their RHC.

Where it is running

• Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.